# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Harriet Tubman (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI005-SYN
- Date: 2026-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carmen Ruiz-Delgado, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Neurology evaluation of lifelong spells and headache after a head injury. **S**

## History of present illness

Mrs. Tubman is seen two weeks after her primary care visit for headaches on most days and sudden sleep spells since a severe head injury in her early teens. She stopped daily ibuprofen at that visit. Her headaches were worse for the first several days and have eased since; she has used acetaminophen on no more than 2 days a week and is keeping a headache diary. The spells continue several times a day, often while seated in conversation or at meetings, and end after a few minutes; she wakes and picks up where she left off. Witnesses have described no stiffening, jerking, lip-smacking, tongue biting, or incontinence, and she is not confused afterward. She has never had sudden weakness with laughter or strong emotion. She does not drive. She does not want medicine that makes her duller. **S**

| Element | Detail |
|---|---|
| Spells | Several a day, mostly while seated; last a few minutes and end abruptly |
| Witnessed features | No stiffening, jerking, automatisms, tongue biting, incontinence, or confusion afterward |
| Cataplexy | None |
| Headache since stopping ibuprofen | Worse for several days, then easing |
| Acute medicine | Acetaminophen on no more than 2 days a week; no ibuprofen |
| Driving | Does not drive |
| Patient preference | No sedating medicine |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Headaches most days and sudden sleep spells; no weakness, numbness, or speech change |
| Constitutional | Negative | No fever or weight loss |
| Eyes | Negative | No double vision or visual loss |
| Cardiovascular | Negative | No palpitations, chest pain, or fainting on standing |
| Psychiatric | Negative | Mood steady |

5 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth as needed for headache, no more than 2 days a week **S**
- Candesartan 8 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 140/84 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 52 kg; BMI 22.5 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Alert and engaged; no spell during the visit |
| Head | Palpable depression of the left frontal skull, healed |
| Fundi | Sharp discs; no papilledema |
| Cranial nerves | Intact |
| Motor and sensory | Normal strength, tone, and sensation |
| Coordination and gait | Normal finger-nose testing and gait |
| Reflexes | Symmetric |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Recurrent sudden spells since adolescent head injury, cause under evaluation**. Brief spells that end abruptly with full recovery and no convulsive or post-ictal features favor sleep attacks over focal seizures. Routine EEG today shows intermittent left frontal slowing over the old injury but no epileptiform discharges; MRI shows an old depressed left frontal skull defect with small underlying encephalomalacia and normal hippocampi. **S**
   - Ambulatory EEG with video to capture typical spells.
   - Overnight polysomnography followed by a multiple sleep latency test.
   - No antiseizure medicine unless the spells prove epileptic.
   - Safety advice for sudden sleep: sit down at the first sign of sleepiness; she does not drive.
2. **Chronic post-traumatic headache** (G44.329). Headache on most days since the injury, worsened by analgesic overuse. Blood pressure 140/84 mmHg. A non-sedating preventive is preferred. **S**
   - Start candesartan 8 mg daily for headache prevention; it also lowers her mildly raised blood pressure.
   - Potassium and creatinine in four weeks, before increasing the dose.
   - Continue the headache diary.
3. **Medication-overuse headache, withdrawal under way** (G44.40). Two weeks without ibuprofen; the expected withdrawal worsening has passed. **S**
   - Acetaminophen on no more than 2 days a week; no NSAIDs.
4. **Sequelae of adolescent traumatic brain injury** (S06.9XAS). Old left frontal skull defect with small encephalomalacia on MRI, consistent with the historical injury; no new lesion. **S**
   - No further imaging unless new neurological signs appear.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Referral | Neurology evaluation of possible seizures | After a first or uncertain seizure | Completed today | Seen today |
| Examination | Routine EEG | After a possible seizure | Completed today | Intermittent left frontal slowing; no epileptiform discharges |
| Imaging | MRI of the brain | After a possible seizure | Completed today | Old depressed left frontal skull defect with small encephalomalacia; normal hippocampi; no tumor |
| Examination | Ambulatory EEG with video to capture typical spells | When routine EEG is not diagnostic | Ordered | Booked for early next month |
| Examination | Overnight polysomnography and multiple sleep latency test | For excessive daytime sleepiness | Ordered | Booked after the ambulatory EEG |
| Survey | PROMIS sleep-related impairment | At baseline and after treatment | Up to date | T-score 68 two weeks ago; repeat at the results visit |
| Medication safety | Antiseizure medicine | Only if spells prove epileptic | Not indicated | Not started; awaiting the ambulatory EEG |
| Self-management | Headache diary (headache days and acute-medicine days) | Daily | Completed today | Started two weeks ago and reviewed today |
| Medication safety | Acute headache medicine on no more than 2 days a week | Every visit | Completed today | No ibuprofen since the first visit; acetaminophen within the limit |
| Survey | Headache days per three months | At baseline and 2 to 3 months after starting prevention | Up to date | 54 days in the three months before intake; reassess at the three-month review |
| Examination | Blood pressure, heart rate, and weight | Every visit | Completed today | 140/84 mmHg, pulse 70, weight 52 kg; baseline before candesartan |
| Laboratory | Basic metabolic panel (potassium and creatinine) on candesartan | Before starting and a few weeks after; then periodically | Up to date | Baseline two weeks ago: potassium 4.2, creatinine 0.84, eGFR 72. Recheck in four weeks |
| Self-management | Safety advice for sudden sleep episodes | Every visit | Completed today | Reviewed with her today; she does not drive |
| Survey | Depression screen (PHQ-9) | At baseline and at follow-up | Up to date | Score 3 at intake; repeat at the three-month review |

## Goal progress

- Stop daily over-the-counter analgesics and limit acute headache medicine to no more than 2 days a week. In progress; target 2026-05-18. **S**
- Cut headache days by at least half by the three-month review. In progress; target 2026-08-17. **S**
- Reduce daytime sleep attacks and lower the PROMIS sleep-related impairment T-score below 60. In progress; target 2026-08-17. **S**
- Establish whether the spells are epileptic before considering antiseizure medicine. In progress; target 2026-05-18. **S**

## Medication changes

- Started: Candesartan 8 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- Evidence-based guideline: Management of an unprovoked first seizure in adults (Krumholz A, et al. Neurology 2015;84(16):1705-1713) (2015), American Academy of Neurology and American Epilepsy Society
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline (Maski K, et al. J Clin Sleep Med 2021;17(9):1881-1893) (2021), American Academy of Sleep Medicine
- The International Classification of Headache Disorders, 3rd edition (Cephalalgia 2018;38(1):1-211) (2018), Headache Classification Committee of the International Headache Society
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (Ailani J, et al. Headache 2021;61(7):1021-1039) (2021), American Headache Society

## Follow-up

- Ambulatory EEG, then polysomnography and a multiple sleep latency test. Results visit with potassium and creatinine in four weeks. **S**
- Next scheduled visit 2026-05-18: review of ambulatory EEG and sleep studies; four-week headache check. **S**
